Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

Lakhan SE, Rowland M.

BMC Neurol. 2009 Dec 4;9:59. doi: 10.1186/1471-2377-9-59. Review.

2.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.

PMID:
24671907
3.

Advances in the management of multiple sclerosis spasticity: recent clinical trials.

Fernández O.

Eur Neurol. 2014;72 Suppl 1:9-11. doi: 10.1159/000367616. Epub 2014 Sep 26.

PMID:
25278117
4.

Medicinal cannabis extracts for the treatment of multiple sclerosis.

Smith PF.

Curr Opin Investig Drugs. 2004 Jul;5(7):727-30.

PMID:
15298068
5.

Sativex for the management of multiple sclerosis symptoms.

Perras C.

Issues Emerg Health Technol. 2005 Sep;(72):1-4.

PMID:
16317825
6.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.

PMID:
21456949
7.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group..

Eur J Neurol. 2007 Mar;14(3):290-6.

PMID:
17355549
8.

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Wade DT, Robson P, House H, Makela P, Aram J.

Clin Rehabil. 2003 Feb;17(1):21-9.

PMID:
12617376
9.

THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.

Trojano M.

Eur Neurol. 2016;75 Suppl 1:4-8. doi: 10.1159/000444235. Epub 2016 Feb 23.

PMID:
26901343
11.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Gras A, Broughton J.

Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):771-779. Epub 2016 Feb 26.

PMID:
26750641
12.

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.

Serpell MG, Notcutt W, Collin C.

J Neurol. 2013 Jan;260(1):285-95. doi: 10.1007/s00415-012-6634-z. Epub 2012 Aug 10.

PMID:
22878432
13.
14.

Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.

Koehler J, Feneberg W, Meier M, Pöllmann W.

Int J Neurosci. 2014 Sep;124(9):652-6. doi: 10.3109/00207454.2013.877460. Epub 2014 Jan 23.

PMID:
24392812
15.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
16.

THC:CBD spray and MS spasticity symptoms: data from latest studies.

Rekand T.

Eur Neurol. 2014;71 Suppl 1:4-9. doi: 10.1159/000357742. Epub 2014 Jan 22. Review.

PMID:
24457846
17.
18.
19.
20.

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.

Moreno Torres I, Sanchez AJ, Garcia-Merino A.

Expert Rev Neurother. 2014 Nov;14(11):1243-50. doi: 10.1586/14737175.2014.971758. Review.

PMID:
25331416

Supplemental Content

Support Center